{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-037255","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.963459+00:00","generated_at":"2026-05-16T13:47:54.131555+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pulse Biosciences initiates thyroid cancer study with MD Anderson; IDE approved","bullets":["FDA-approved IDE for first-in-human feasibility study of nPulse Vybrance system in papillary thyroid microcarcinoma.","Study to commence early 2026, enroll 30 subjects at two sites, led by Dr. Victoria Banuchi at MD Anderson.","Preclinical studies ongoing for anaplastic thyroid carcinoma, a rare cancer with <5% five-year survival rate.","nPulse technology uses nonthermal nsPFA to limit scarring and damage to surrounding structures."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-037255","json":"https://secwatch.observer/filing/0001437749-25-037255.json","markdown":"https://secwatch.observer/filing/0001437749-25-037255.md","text":"https://secwatch.observer/filing/0001437749-25-037255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925037255/0001437749-25-037255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925037255/plse20251208_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:47:54.131555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}